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Poster Session I S241Myeloablative conditioning regimens may cause life threatening
transplant related toxicities in patients with primary immunodefi-
ciency disorders (PID), particularly in patients with co-morbid con-
ditions. We previously reported the outcomes of a phase I study
using nonmyeloablative conditioning in 14 high-risk patients and
demonstrated low transplant related mortality (TRM; 3-year,
23%); however there was a high incidence of chronic GVHD (1-
year 47%). We reasoned that the incidence of GVHD could be re-
duced if marrow was used instead of PBSC; however, previous expe-
rience showed marrow to be associated with a higher risk for
rejection. Therefore our standard nonmyeloablative regimen of
90 mg/m2 fludarabine and 2 Gy total body irradiation (TBI) was
somewhat intensified to include either Campath 1-H, or, for patients
with infections for whom Campath 1-H was contraindicated, an ad-
ditional 2 Gy TBI.
Sixteen patients with PID and significant underlying infections
and/or other co-morbidities were given HLA-matched related
(n5 7) or unrelated (n5 9) marrow grafts following nonmyeloabla-
tive conditioning modified with either Campath 1-H (n5 3) or 4 Gy
TBI (n5 13). All patients were given postgrafting immunosuppres-
sion with MMF and CSP. Of the 15 patients evaluable for engraft-
ment, mixed (50-95%; n5 8) or full (.95%; n5 6) donor
CD3 +T-cell chimerismwas established in 14 patients. Two patients
required a 2nd myeloablative HCT due to graft rejection or loss of
the granulocyte and NK cell components of the graft despite stable
mixed T-cell chimerism. The cumulative incidence of extensive
chronic GVHD at 1 year was 29%. With a median follow-up of 19
(range, 3 – 36) months the 1-year overall survival and TRM were
87% and 14%, respectively. One patient with disseminated CMV
and adenovirus before HCT died from these infections at day +1
and one patient with pre existing renal failure died at day +222
from complications of renal failure. Five patients were not evaluable
for disease response due to less than 100 days of follow-up (n5 2),
2nd HCT (n5 2), or death prior to day 100 following HCT
(n5 1). Eleven patients had improvement in or correction of their
underlying immunodeficiency. Although preliminary, these results
indicate that outcome can be improved for high-risk patients with
PID using a modified nonmyeloablative conditioning regimen and
marrow grafts, resulting in reduction of chronic GVHD, stable do-
nor engraftment, low TRM, and correction of underlying disease
processes.224
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This is a multi-center, case controlled, retrospective study of the
short-term and 1-year outcomes of children who received intensive
cardiopulmonary (CP) support during theHSCT admission at seven
tertiary care facilities. Intensive CP support was defined as the need
for continuous positive pressure ventilation, dopamine greater than
or equal to10 mcg/kg/min, or the use of other cardiotropic drug.
We compared the outcomes of 94 patients who required intensive
CP care to 282 patients hospitalized during the same period who
did not receive intensive CP support. Demographic and transplant
data are summarized below. Respiratory failure was the most com-
mon indication for CP care (75.5%) followed by sepsis (10.6%), neu-
rologic event (4.3%), cardiac compromise (2.1%), multi-system
organ failure (MSOF) (2.1%), and other causes (5.4%). Acute
GVHD was present in 21% of patients and macroscopic bleeding
in 26% at the onset of CP support. 46% of patients had a pediatric
logistic organ dysfunction score of at least 1 in two organ systems
at the start of CP support. 44% of patients needed noninvasive ven-
tilation (median duration 2 days). Of this 44%, 66% later required
invasive ventilation, 22% successfully discontinued support, and
12% died. 82% of CP patients received invasive ventilation (medianduration 8 days) and 38% died prior to discharge. 50% of patients
needed cardiac medications. The median duration CP support was
18.6 days. 44.7% of patients died prior to discharge from CP sup-
port, 52.1% transitioned to non-intensive CP care, and 3.2% re-
turned to the HSCT unit for palliation. MSOF was the most
common cause of death (51%). 39% of patients who survived initial
CP support needed additional intensive CP care and 58% of these
patients died prior to discharge. Survival to hospital discharge was
37.2% in the CP group and 98.9% in the non-CP group. OS at 1-
year was 32% and 78% in the CP and non-CP groups. The 1-year
overall survival (86% vs. 79%) and disease-free survival (69% vs
72%) of CP and non-CP patients who survived to hospital discharge
were not significantly different. The 1-year relapse rate, incidence of
GVHD, mean FEV1, shortening fraction, and creatinine were not
significantly different between the two groups. The survival rate of
pediatric patients requiring intensive CP support has improved,
but remains suboptimal. No significant difference existed in 1-year
organ function or survival among patients who did or did not receive
intensive CP support.
Demographic and Transplant Data
Case, n5 94 Control, n5 282Age median (months) 67 97
Diagnosis (%)ALL CR1/CR2 5.3/12.8 8.9/17
AML CR1/CR2 7.4/5.3 11/8.5
Metabolic Disease 12.8 8.5
Immunodeficiency 1.7 4.3
Nonmalignant Hematologic
Disease10.6 9.5Solid Tumor 13.8 17.7
Myelodysplasia 2.1 1.8
HLH 6.4 0.7
Lymphoma 4 5
Osteopetrosis 3.2 0.4
JMML 2.1 0.7
Other 5.3 6.5
Autolgous HSCT 18.1 18.4
Allogeneic HSCT 81.9 81.5Donor Source (%)
6/6 Related Donor 14.3 35.8
\ 6/6 Related Donor 9.1 6.6
6/6 Unrelated Donor 26 26.2
\6/6 Unrelated Donor 50.6 31.4225
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Hemophagocytic lymphohistiocytosis (HLH) is a rare and usually
fatal hyperinflammatory disorder associated with genetic defects of
CD8 +T cell and NK cell cytotoxic function. Jordan, et al (Blood
2004;104(3):735-43) previously showed that perforin-deficient
(prf-/-) mice infected with lymphocytic choriomeningitis virus
(LCMV) develop a disorder which is essentially identical to human
HLH. In this animal model of HLH, ineffective cytotoxic
CD8 +T cells fail to down-modulate stimulatory signals from anti-
gen presenting cells. Exaggerated T cell responses are responsible
for massive cytokine production, especially interferon-gamma
(IFN-g), which drives systemic macrophage activation and results
in HLH-like disease pathology. Thus, at least three critical events
occur in the pathogenesis of HLH: 1) abnormal increase in antigen
presentation, 2) abnormal increase in CD8 +T cell activation and cy-
tokine secretion, and 3) pathological macrophage activation.
Survival with current standard HLH therapy, consisting of cyto-
toxic chemotherapy (etoposide) and nonspecific immunosuppression
(dexamethasone), is approximately 75% at 8 weeks. Ongoing studies
using ourmurinemodel of HLH indicate that etoposide acts primar-
ily by deleting activated IFNg-producingT cells.While beneficial in
